Curative management of a cardiac metastasis from lung cancer revealed by an electrical storm.

Cardiac metastasis Lung cancer SBRT

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 30 04 2019
revised: 19 10 2019
accepted: 26 10 2019
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 30 1 2020
Statut: epublish

Résumé

Although cardiac metastases (CM) are more common than primary cardiac malignant tumors, they remain a rare localization of metastatic cancer. Until recently, CM were surgically treated as a palliative approach because of a lack of ablative solutions even for oligometastatic patients. Technological advances in radiation therapy (RT) in thoracic oncology have led to high precision delivery that enlarged the indications for stereotactic body radiotherapy (SBRT). To date, there are limited reports of cardiac SBRT for CM. Herein, we report a cardiac SBRT performed in curative intent for a lung cancer patient metastatic to the heart.

Identifiants

pubmed: 31993511
doi: 10.1016/j.ctro.2019.10.005
pii: S2405-6308(19)30105-3
pmc: PMC6976909
doi:

Types de publication

Case Reports

Langues

eng

Pagination

62-65

Informations de copyright

© 2019 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

Déclaration de conflit d'intérêts

The authors report no conflict of interest related to this work. The authors alone are responsible for the content and writing of the paper.

Références

Radiol Med. 2013 Sep;118(6):1055-65
pubmed: 23716288
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Pract Radiat Oncol. 2019 Jan;9(1):5-8
pubmed: 30611463
J Thorac Oncol. 2010 Jan;5(1):29-33
pubmed: 19952801
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Eur J Surg Oncol. 2017 Oct;43(10):1901-1907
pubmed: 28888801
Int J Clin Oncol. 2008 Aug;13(4):369-72
pubmed: 18704641
Front Oncol. 2018 May 09;8:154
pubmed: 29868476
Cardiol Res. 2012 Apr;3(2):47-48
pubmed: 28348671
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
Radiother Oncol. 2018 Aug;128(2):189-191
pubmed: 29753550
Cancer Med. 2016 Jun;5(6):989-96
pubmed: 26880683
J Clin Pathol. 2007 Jan;60(1):27-34
pubmed: 17098886
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687

Auteurs

Raphael Jumeau (R)

Radiation Oncology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Maria Gabriella Vincenti (MG)

Cardiology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Etienne Pruvot (E)

Cardiology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Juerg Schwitter (J)

Cardiac MR Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Veronique Vallet (V)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Michele Zeverino (M)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Raphael Moeckli (R)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Hasna Bouchaab (H)

Oncology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Jean Bourhis (J)

Radiation Oncology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Mahmut Ozsahin (M)

Radiation Oncology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Classifications MeSH